Federally qualified health centers (FQHCs) saw the benefit of funding from an American Cancer Society (ACS) program aimed at strengthening colorectal cancer screening rates over a 3-year period.
An American Cancer Society (ACS) program was effective at strengthening colorectal cancer (CRC) screening rates in federally qualified health centers (FQHCs), a study suggested.
The study appears early online in the American Journal of Preventive Medicine. The authors said it has implications for broader public health efforts to increase cancer prevention and screening.
In 2013, ACS initiated the Community Health Advocates Implementing Nationwide Grants for Empowerment and Equity (CHANGE) grant program, which was designed to reduce breast and CRC screening disparities by building community capacity to implement evidence-based interventions proven to increase cancer screening rates. Funding is awarded to FQHC partners, with technical assistance provided by ACS field staff.
Funded FQHCs were required to implement at least 1 provider-oriented strategy (provider assessment and feedback or provider reminder/recall systems) and at least 1 client-oriented strategy (education, client reminders, or navigation). Most grantees (88.4%) implemented 3 to 5 intervention strategies throughout their funding period.
Investigators compared screening rates of FQHCs funded by CHANGE grants to those of matched controls. At the start of the study period, CRC screening rates were low across the board, with funded FQHCs lagging nonfunded FQHCs (26.4% vs 30.4%).
In the first year (2013-2014), funded FQHCs increased their CRC screening rates significantly more than nonfunded FQHCs. Funded FQHCs increased by 8.7% (from 26.4% to 35.1%) while nonfunded FQHCs increased by 2.7% (from 28.5% to 31.2%).
Across the 3 years, increases were 12.7% (from 26.4% to 39.1%) and 9% (from 28.5% to 37.5%), respectively. The difference in change rates between groups across the 3 years was not significant.
"Even in the absence of the ACS grant funds, many FQHCs increased their CRC screening rates substantially during the 3-year period," write the authors. "The 80% by 2018 CRC campaign is a national initiative that serves as a catalyst for concentrated focus on CRC screening and may have contributed to an overall increase in CRC screening rates."
They emphasize that such specific funding, along with data accountability and reporting, can improve policies and practices to eventually increase screening rates among uninsured and underserved populations.
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Collecting SDOH Data Can Assess Risk of Medical Nonadherence, Improve HEI and Star Ratings
April 18th 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.
Read More
Many Patients With Psoriasis in Clinical Trials Experience Nocebo Effects, Study Finds
April 18th 2024Half of patients exposed to placebo in clinical trials experienced adverse events (AEs), which may be partially explainable by nocebo effects, according to a recent review and meta-analysis.
Read More